New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. (2nd January 2017)

• Record Type: Journal Article
• Authors: Genova, Carlo; Rijavec, Erika; Biello, Federica; Rossi, Giovanni; Barletta, Giulia; Dal Bello, Maria Giovanna; Vanni, Irene; Coco, Simona; Alama, Angela; Grossi, Francesco
• Is Part Of: Expert opinion on pharmacotherapy. Volume 18:Number 1(2017)
• Page Start: 19
• Page End: 33
• Publication Date: 2017-01-02
• Subjects: EGFR -- ALK -- resistance -- non-small cell lung cancer -- T790M; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2016.1261109
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Although the achievements in the treatment of advanced non-small cell lung cancer (NSCLC) have been translated in improved disease control, response rate and survival, especially in the case of patients with targetable oncogenic drivers, acquired resistance is common after initial benefit; furthermore, primary resistance can occasionally be observed. Due to its clinical implications, the management of treatment-resistant NSCLC is a top topic of the current research, and many efforts are being put in the study of the mechanisms at the base of resistance and in the development of effective therapeutic countermeasures. Areas covered : This review aims at identifying the most relevant novel chemical therapies designed to overcome resistance in NSCLC, including recently approved agents, as well as compounds in clinical development. Expert opinion : An improved knowledge of the mechanisms causing resistance to treatments in NSCLC translates into effective innovative chemical therapies able to overcome such occurrence, and the paradigms of this progress are represented by novel inhibitors of the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK); however, the study of novel systemic therapies in this setting is challenging, and further efforts in this setting are highly needed.